Silence Therapeutics Share Discussion Threads

[callumross] 26/9/2016 16:01

I've a feeling that it will be announced that atu027 has been discontinued but kind of already in the price, I suspect. Hopefully, other developments will more than counterbalance this.

[1gw] 26/9/2016 15:21

What chance things get a bit busier tomorrow with the interims?

[1gw] 09/9/2016 15:15

Nice to see another bounce today, this time on what looks like low volume. Not at all clear to me why it's bouncing though...

[beergut] 11/8/2016 10:02

Are we expecting any news now the price has picked up together with the volume?

[rogen83] 09/8/2016 14:44

probably MTFB not being able to do a dual listing having an impact on sentiment but SLN dropped on such low volume I suspect there is nothing 'real' behind it

[beergut] 09/8/2016 14:09

Any known reason for the drop this afternoon...

[callumross] 26/7/2016 20:15

Interesting read gersemi - thank you.

[rogen83] 19/4/2016 07:19

well the CEO is confident with that share purchase even if no one else is. follow the money....

[rogen83] 06/4/2016 12:56

i think you're being a bit harsh

[barrieb] 06/4/2016 08:33

MrsA - care to enlarge on your statement as I would call it realistic and to the point which I like but I dont have your experience is these matters.

2015 was a difficult year for the biotechnology sector globally but a significant one for Silence Therapeutics. Modulating gene expression on and off in vivo remains a serious technical challenge. However, for the first time in its history, the Company has the combination of world leading technologies and the balance sheet to create a world class biopharma company.

We believe we are making material improvements in new delivery systems as seen in the progress we have made in GalNAc siRNA conjugates. The ability to mediate RNAi in the liver subcutaneously as opposed to an invasive intravenous injection opens up entirely new indications which were not accessible to a liposomal system.

In addition to progress in delivery, our proprietary siRNA chemistry AtuRNAi has been strengthened with the granting of a new US patent. Although parts of our patent estate start to expire in 2023, the importance of our chemical modification technology is being realised as siRNA pipelines are maturing. We now expect to be able to capitalise on our intellectual property which was first filed in 2003.

With the commencement of the Quark trials, the approach from a potential licensee and the significant broadening of the AtuRNAi patent estate, we are of the belief that these opportunities alone could be very significant relative to the current size of the Company."

[mrsapeslaptop] 05/4/2016 19:18

what an appalling results statement. blimey.

[djnzloop] 18/3/2016 16:09

Even if they had some positives I don't reckon they'll release any meaningful RNS until sector shows some improvement. The market just isn't listening to Biotech.

[barrieb] 18/3/2016 11:38

Does anyone know if we are awaiting any news.

[rogen83] 18/3/2016 11:09

its a lack of newsflow, shares drift with no news flow. Watch the heard pile in when there is something to talk about

[buywell3] 18/3/2016 11:02

The chart will tell you


buywell3 26 Nov'15 - 00:50 - 47117 of 47119 0 0 edit

Remember

9 out of 10 small pharma-biotechs NEVER make it into profits

Or put another way

Only 9% of small cap pharma-biotechs ever reach profitability ... the rest perish


Thus if you can find one that does ... at an early stage .... it could prove to be a good investment

[barrieb] 18/3/2016 11:00

anyone in?

This is our old 1.4p

Any idea where the bottom will be?

[partner] 15/1/2016 09:00

was that our seller finally cleared yesterday .

[buywell3] 26/11/2015 00:50

Remember

9 out of 10 small pharma-biotechs NEVER make it into profits

Or put another way

Only 9% of small cap pharma-biotechs ever reach profitability ... the rest perish


Thus if you can find one that does ... at an early stage .... it could prove to be a good investment

[callumross] 31/10/2015 14:39

Milestone payments announced yesterday are for Quark entering Phase 3 and are IN ADDITION to the 15% which is still only a possibility depending on the outcome of phase 3 trials (the primary endpoint in the quark Phase 2 trial of 30% was achieved in a very specific subset of patients amounting to 50% of the trial participants). Surprised we didn't see a strong bounce in the share price on the announcement yesterday.

[pwilk47490] 31/10/2015 07:10

Thanks callumross.

So let me get this right. We hold the Patent for QPI-1002. But we work with Quark in its development? Which Quark pays us to use?

But now Quark have sold worldwide licence on to Novartis? And if they use it we are eligible for 15% of the proceeds?

Sorry, a bit confused.